12:00 AM
 | 
Sep 07, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Symlin pramlintide: Phase III

In AMLN's one-year 656-patient U.S. Phase III trial of Symlin in combination with insulin and oral hypoglycemic agents, patients receiving 120 ug Symlin twice per day (BID) had a 0.7 percent reduction in the primary end point of glycated hemoglobin (HbA1c) at 6 months compared to a reduction of 0.3 percent in the placebo group (p=0.003). That benefit was sustained at one year, with...

Read the full 296 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >